GLO1 and HIV-1 infection: Intravenous administration of AAV2/9-Endo-Glo1 to Hu-mice five weeks after HIV-1 infection blunted the impairment in microvascular permeability and microvascular leakage seen in heart at seventeen weeks post-infection (Figure 6A, lower right panel).